CYTEIR THERAPEUTICS INC (CYT)
US23284P1030 - Common Stock
ChartMill assigns a Buy % Consensus number of 45% to CYT. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 3.06. This target is 1.32% above the current price.
CYT was analyzed by 8 analysts. The buy percentage consensus is at 45. So analysts seem to be rather negative about CYT.
In the previous month the buy percentage consensus was at a similar level.
CYT was analyzed by 8 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-01-05 | B of A Securities | Downgrade | Neutral -> Underperform |
| 2023-05-12 | Wedbush | Reiterate | Outperform -> Outperform |
| 2023-02-03 | Morgan Stanley | Downgrade | Equal-Weight -> Underweight |
| 2023-01-30 | B of A Securities | Downgrade | Buy -> Neutral |
| 2023-01-20 | JP Morgan | Downgrade | Overweight -> Neutral |
| 2022-09-09 | Morgan Stanley | Downgrade | Overweight -> Equal-Weight |
| 2022-02-07 | Northland Capital Markets | Initiate | Outperform |
| 2021-07-13 | Wedbush | Initiate | Outperform |
| 2021-07-13 | JP Morgan | Initiate | Overweight |
| 2021-07-13 | B of A Securities | Initiate | Buy |
| 2021-07-13 | Morgan Stanley | Initiate | Overweight |